from that review, focuses on the comparative effectiveness and safety of (1) aspirin versus placebo or no antiplatelet, (2) clopidogrel versus aspirin, (3) clopidogrel plus aspirin versus aspirin alone, and (4) other antiplatelet comparisons.
Methods Data Sources and Searches
Searches were limited to articles published from January 1995 to August 2012. Exact search strings are listed in the full Agency for Healthcare Research and Quality (AHRQ) report. 2 We supplemented electronic searches with a manual search of references from systematic reviews and pivotal articles in the field. We also searched the gray literature of study registries and conference abstracts for relevant articles from completed studies that have not been published in a peer-reviewed journal, including ClinicalTrials.gov, the World Health Organization's International Clinical Trials Registry Platform Search Portal, and the ProQuest COS Conference Papers Index. Scientific information packets were requested from manufacturers of medications and devices and reviewed for relevant articles.
Study Selection
Studies were limited to adult populations aged 18 years or older with lower-extremity PAD. English-language randomized or observational studies were included. Detailed inclusion and exclusion criteria are in the full report. 2 
Data Extraction and Quality Assessment
Abstracted data included study design, patient characteristics overall and by study group (age, sex, and race), vascular disease risk factors (diabetes, tobacco use, chronic kidney disease, hyperlipidemia, or other comorbid diseases), and interventionspecific factors (antiplatelet therapy, and, if applicable, type of endovascular or surgical revascularization). Outcomes captured included overall morality, CV mortality, nonfatal myocardial infarction (MI), nonfatal stroke, repeat revascularization, vessel patency, and composite CV events (CVEs; CV mortality, nonfatal MI, and nonfatal stroke). Safety outcomes included adverse drug reactions and bleeding. Disagreements were resolved by consensus.
We evaluated the quality of individual studies as described in the AHRQ's "Methods Guide for Effectiveness and Comparative Effectiveness Reviews," 3 assigning summary ratings of good, fair, or poor.
Data Synthesis and Analysis
Continuous variable outcomes were summarized as reported by the investigators. This included means, medians, standard deviations, interquartile ranges, ranges, and associated P values. Dichotomous variables were summarized by proportions and associated P values. We then determined the feasibility of completing a quantitative synthesis (ie, metaanalysis). Feasibility depended on the volume of relevant literature, conceptual homogeneity of the studies, and completeness of the reporting of results. We considered metaanalysis for comparisons where at least 3 studies reported the same outcome at similar follow-up intervals. However, no metaanalyses were performed owing to insufficient numbers of similar studies that could be combined. Thus, forest plots with the individual study results were created for a graphical display of the findings relative to each other. Two reviewers evaluated the strength of evidence (SOE) using the 4 required domains described in the AHRQ's "Methods Guide" 3 : risk of bias, consistency, directness, and precision. We assigned an overall grade for the SOE as high (evidence reflects the true effect), moderate (further research may change the estimate of effect), low (further research is likely to change the estimate), or insufficient (an estimate of effect is not possible with the available data). When appropriate, we also evaluated studies for coherence, dose-response association, residual confounding, strength of association (magnitude of effect), publication bias, and applicability.
Results
We identified 11 unique studies that evaluated the comparative effectiveness of aspirin and antiplatelet agents in 15 500 patients with PAD. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Of these studies, 7 were graded good quality, 3 fair, and 1 poor. Figure 1 depicts the flow of articles through the literature search and screening process. Table 1 gives an overview of the antiplatelet comparisons, populations, designs, and primary outcomes for the studies included in the analysis. SOE (Table 2) varied by PAD population and clinical outcome for each treatment comparison. Figure 2 shows the hazard ratios (HRs) for various outcomes in the randomized, controlled trials (RCTs) comparing aspirin versus placebo. In the asymptomatic population at ≥2 years, aspirin compared with placebo had no statistically significant effect on CV mortality (moderate SOE), nonfatal MI, nonfatal stroke, or composite CVEs (CV mortality, nonfatal stroke, and nonfatal MI) (all high SOE).
Aspirin Versus Placebo or No Antiplatelet
In the IC population at ≥2 years, there was a significantly lower rate of MI and composite events in the aspirin group, compared to placebo (low SOE), but no significant difference in rates of nonfatal stroke or CV mortality (insufficient SOE). The observational study 7 reported one nonfatal MI (1.2%), 2 strokes (2.5%), and 26 (33%) vascular deaths in the aspirin treatment arm and 2 nonfatal MIs (5.9%), 3 strokes (8.8%), and 9 (26%) vascular deaths in the noaspirin treatment arm 2 years after infrainguinal bypass for CLI (low SOE for all outcomes).
Clopidogrel Versus Aspirin Figure 3 shows the HRs for CV mortality, nonfatal MI, nonfatal stroke, and the composite outcome for the above for clopidogrel monotherapy versus aspirin monotherapy in the PAD subgroup of the CAPRIE study. 10 There was a statistically significant benefit of clopidogrel monotherapy over aspirin monotherapy in regard to CV mortality, nonfatal MI, and composite CVEs (CV mortality, nonfatal stroke, and nonfatal MI) (moderate SOE), but no difference in the rates of nonfatal stroke (low SOE).
Clopidogrel Plus Aspirin (Dual Antiplatelet) Versus Aspirin Alone Figure 4 shows the HRs for the various outcomes reported in studies examining dual antiplatelet versus aspirin. There was no significant difference in all-cause mortality for clopidogrel plus aspirin (DAPT), compared with aspirin alone. It was not possible to calculate an HR for all-cause mortality in the MIRROR study 16 because no patients in the dual antiplatelet group died; we calculated an odds ratio (OR) of 0.33 (95% confidence interval [CI], 0.01 to 8.22 ) showing a nonsignificant reduction in deaths in the dual antiplatelet group. There was a statistically significant decrease in nonfatal MI for DAPT, compared with aspirin alone, in the CHARISMA study 11 and a nonsignificant decrease in the CASPAR study (low SOE). 15 Neither study showed a significant difference of DAPT over aspirin alone for nonfatal stroke (low SOE), CV mortality (low SOE), or composite CVEs (moderate SOE). The CASPAR and MIRROR studies reported revascularization rates (insufficient SOE). The CAS-PAR study showed no significant difference in revascularization (HR, 0.89; 95% CI, 0.65 to 1.23); however, the occlusion rate in the prosthetic graft subgroup was lower in patients who received DAPT at 24 months (HR, 0.64; 95% CI, 0.42 to 0.63; P=0.21). 15 The MIRROR study had 2 dual antiplatelet patients (5%; both clopidogrel resistant) and 8 aspirin patients (20%) who had target vessel revascularization at 6 months (P=0.04). 16 
Other Antiplatelet Comparisons
Two fair-quality RCTs assessed other antiplatelet comparisons in patients with IC or CLI. 9, 10 The study by Horrocks et al compared aspirin or iloprost versus no antiplatelet agent in patients with IC or CLI after percutaneous transluminal angioplasty (PTA) and found no significant difference in restenosis or reocclusion rates between treatment groups (aspirin 38.5% versus iloprost 0% versus placebo 21.4%). 8 The study by Minar et al compared aspirin 1000 mg with aspirin 100 mg in patients with IC or CLI after femoropopliteal PTA and found no significant difference in total mortality (13.4% versus 12.3%, respectively) or vessel patency (62.5% versus 62.6%, respectively) between treatment groups. 9 Neither study reported a composite outcome. Table 3 highlights outcomes from 4 studies (3 good quality and 1 fair) that reported variations in treatment effectiveness by subgroup. 4, 5, 9, 13 The POPADAD study compared aspirin with placebo in asymptomatic or high-risk patients and found no significant differences in outcome based on age, sex, or ankle-brachial index (ABI). 4 Another study by Fowkes et al, also comparing aspirin with placebo in asymptomatic or highrisk patients analyzed results by age, sex, and ABI and found no significant variation in outcomes. 5 The study by Minar et al, 9 which compared high-with low-dose aspirin, also analyzed results by sex and found similar outcomes in men and women. One study by Belch et al showed a benefit of clopidogrel plus aspirin for reducing composite vascular events in patients with a prosthetic bypass graft, compared to those with a venous bypass graft. 15 We found no studies reporting subgroup results by race or risk factors (eg, tobacco use or presence of hyperlipidemia). Given the heterogeneity of the subgroups, interventions, and clinical outcomes, the SOE for modifiers of effectiveness was insufficient. strategy. [4] [5] [6] 11, [14] [15] [16] All 7 studies reported bleeding, gastrointestinal (GI) bleeding, or anemia as a harm. A quantitative analysis of bleeding rates was not possible owing to the low number of studies by treatment comparison, variation in the bleeding definition, and differences in measurement time points. In 2 aspirin versus placebo studies, the rates of major hemorrhage or bleeding were slightly higher in the aspirin groups. 4, 5 A third study showed lower rates of GI bleeding in the aspirin group. 5 In the dual antiplatelet groups, bleeding rates ranged from 2% to 3% (with 1 study showing a rate of 28% in the immediate postoperative period), compared to bleeding rates ranging from 0% to 6% in the placebo groups. There was no significant difference in bleeding except in the immediate postoperative period. 11, [14] [15] [16] Two studies reported the adverse side effect of a rash, which was higher in patients receiving aspirin compared to placebo, 4 and similar in patients receiving DAPT or aspirin. 14 None of the studies reported on whether any harms varied by subgroup (age, sex, race, risk factors, comorbidities, or anatomic location of disease). Therefore, the SOE for safety concerns is insufficient.
Modifiers of Effectiveness

Safety Concerns
Discussion
The 3 major findings of this review are: (1) Aspirin has no benefit in the asymptomatic PAD patient; (2) clopidogrel monotherapy is more beneficial than aspirin in the IC patient;
and (3) DAPT is not significantly better than aspirin at reducing CVEs in patients with IC or CLI. The unique features of this comparative effectiveness review include an assessment of studies published since 1995 to increase applicability to clinical practice, presentation of results by PAD clinical population (asymptomatic, IC, or CLI), and grading of the SOE using AHRQ methodology. We used 1995 as the start date for the literature search to improve the applicability of the findings to current clinical practice in an era when secondary prevention of CVEs includes smoking cessation counseling and treatment of hypertension, diabetes mellitus, and hyperlipidemia. Current guideline recommendations include reaching specific blood pressure, hemoglobin A1c, and lipid-lowering goals as well as providing access to nicotine replacement therapy for smoking cessation. 17 By removing studies preceding 1995, we acknowledge that earlier comparative studies of aspirin and dipyridamole were not included in this review. Including ABI indicates ankle-brachial index; ASA, acetylsalicylic acid; CLI, critical limb ischemia; CV, cardiovascular; CVD, cardiovascular disease; CVE, cardiovascular event; DAPT, dual antiplatelet therapy; HR, hazard ratio; IC, intermittent claudication; MI, myocardial infarction; mg, milligrams; N, number of patients; PAD, peripheral artery disease; PTA, percutaneous transluminal angioplasty; RCT, randomized, controlled trial. Adapted from Jones et al. 2 older studies with outdated background medical therapy for CV risk (CVR) factors may have biased the results to favor active treatment over suboptimal usual-care treatment. We also appreciate that, even in the post-1995 era, there have been differences in the recommendations for, and adherence to, treatment of other CVR factors, which may differentially affect outcomes in older versus more recent studies within this time period.
Data available for antiplatelet agents in PAD treatment fell into 2 categories:subgroup analysis of PAD patients in large antiplatelet RCTs and patients who recently had an endovascular intervention or bypass surgery in smaller antiplatelet RCTs. There are no trials that specifically evaluate the role of antiplatelet agents in a population of patients representing the full spectrum of PAD (asymptomatic, IC, and CLI). Our findings on the effectiveness of aspirin are similar to a meta-analysis of 18 studies published in 2009 by Berger et al. 18 In the subset treated with aspirin alone compared to placebo, they found a nonsignificant reduction in CVEs (defined as nonfatal MI, nonfatal stroke, and CV mortality; relative risk [RR], 0.75; 95% CI, 0.48 to 1.18), a significant reduction in nonfatal stroke (RR, 0.64; 95% CI, 0.42 to 0.99), and no statistically significant reductions in nonfatal MI, CV mortality, or major bleeding. In the Berger et al meta-analysis, 12 of the 18 studies were in patients who were treated before or after a revascularization procedure. We felt this represented a population with evidence of clinical disease and possible interaction with revascularization therapies. The study by Fowkes et al 5 was published after that meta-analysis and is the largest study of asymptomatic patients with PAD who have no established CV disease. Therefore, our review of 3 aspirin versus placebo studies [4] [5] [6] contains the most recent evidence for the effectiveness of aspirin in the current era. Additionally, the current meta-analysis includes more asymptomatic patients treated with aspirin for PAD and may represent a treatment effect by symptom status. The lack of clinical effectiveness of 100 mg daily of aspirin in addition to more-aggressive management of CVR factors is of clinical note and consistent with the meta-analysis by Berger et al, when viewed with regard to background therapy. Our findings support current guidelines that recommend aspirin in symptomatic PAD patients to reduce the risk of MI, stroke, or vascular death, but do not support the recommendations for antiplatelet therapy to reduce the risk of these outcomes in asymptomatic PAD patients.
17
The findings for clopidogrel monotherapy or DAPT were evaluated within subgroups of large, randomized trials. Our finding that clopidogrel monotherapy is superior or equivalent to aspirin monotherapy in reducing adverse CV outcomes from 1 good-quality RCT in a PAD subgroup population represents current clinical practice and helps reinforce the current guideline recommendations for patients with PAD. 10, 17 The role for DAPT compared with aspirin monotherapy is less certain. From the PAD subgroup analysis of 1 large clinical trial 11, 12 and a smaller study on a postrevascularization population, 15 the combination of clopidogrel plus aspirin as DAPT did not show a significant benefit in reducing stroke events or CV mortality in IC patients. In patients with symptomatic or asymptomatic PAD (92% IC and 8% asymptomatic), the PAD subgroup analysis of the CHARISMA study did, however, show a statistically significant benefit favoring dual therapy (clopidogrel plus aspirin) compared with aspirin for reducing nonfatal MI, but showed no difference between aspirin and dual therapy for other outcomes. 11 In the only other systematic review of antiplatelet agents for IC, by the Cochrane group, 19 the report included results of the CAPRIE study, but did not contain results of the CHARISMA or • There appears to be no benefit of aspirin over placebo for all-cause mortality, CV mortality, MI, or stroke (high SOE for all outcomes except CV mortality, which was rated moderate based on 2 good-quality RCTs). Asymptomatic-symptomatic population
• The PAD subgroup analysis of the CHARISMA RCT showed no difference between aspirin and dual therapy (clopidogrel plus aspirin) for outcomes of all-cause mortality (moderate SOE), nonfatal stroke (low SOE), CV mortality (low SOE), or composite vascular events (moderate SOE). There was a statistically significant benefit favoring dual therapy compared with aspirin for reducing nonfatal MI (low SOE).
Intermittent claudication population
• One small, fair-quality RCT suggests with low SOE that aspirin compared to placebo may reduce MI (fatal and nonfatal) and composite vascular events (MI/stroke/pulmonary embolus), but there was insufficient SOE for stroke and CV mortality. The PAD subgroup analysis of the CAPRIE RCT suggests that clopidogrel is more effective than aspirin for reducing CV mortality, nonfatal MI, and composite vascular events (moderate SOE for all outcomes). Clopidogrel and aspirin appear to be equivalent for prevention of nonfatal stroke, but the confidence interval was wide, making this conclusion less certain (low SOE). There is insufficient evidence on the effect of clopidogrel versus aspirin on all-cause mortality. Intermittent claudication or CLI populations
• In patients with IC or CLI after unilateral bypass, the CASPAR RCT showed that dual therapy compared to aspirin resulted in no difference in nonfatal stroke and composite vascular events (low SOE), but there was insufficient SOE for other outcomes.
• In patients with IC or CLI after endovascular procedure, the MIRROR RCT showed no difference between dual therapy and aspirin in CV events or mortality at 6 months, but was insufficiently powered for those outcomes (insufficient SOE). CLI population
• There is insufficient evidence on the effect of aspirin compared to placebo on nonfatal MI, nonfatal stroke, and CV mortality. For all populations
• There is insufficient evidence on the effect of aspirin, clopidogrel, or dual therapy on subgroups, safety events, functional outcomes, or quality of life.
CLI critical limb ischemia; CV, cardiovascular; IC, intermittent claudication; MI, myocardial infarction; PAD, peripheral artery disease; RCT, randomized, controlled trial; SOE, strength of evidence. Adapted from Jones et al. 2 CASPAR studies. That review also included other antiplatelet agents, such as indobufen, picotamide, ticlopidine, and triflusal, which are not prescribed in the United States. Recently, several new antiplatelet agents have been introduced for use in patients with coronary artery disease (CAD). Effectiveness in patients with PAD is not known for most of these new agents; however, a recent study evaluating vorapaxar, a protease-activated receptor-1, did study the effectiveness and safety of vorapaxar or placebo, in addition to standard therapy (88% of patients were on aspirin and 28% of patients were on aspirin plus another P2Y12 inhibitor). This study showed that vorapaxar did not reduce the risk of CV death, MI, or stroke in patients with PAD, compared to placebo, but did significantly reduce acute limb ischemia and peripheral revascularization events. The study also showed that vorapaxar was associated with an increased risk of bleeding. 20 The primary limitation of the available evidence was the low number of studies that compare the effectiveness of aspirin, clopidogrel, and new antiplatelet agents. A single study has compared clopidogrel with aspirin, and 2 studies have compared clopidogrel plus aspirin to aspirin alone. More studies on asymptomatic or symptomatic patients with PAD are needed to firmly conclude whether antiplatelet monotherapy or dual antiplatelet therapy is warranted in this high-risk CV population. In addition, most of the studies were also subgroup analyses of larger antiplatelet trials that used PAD as an inclusion criteria, but randomization was not stratified by PAD. Furthermore, not all studies reported interaction analyses, thus limiting the interpretation of the results for the PAD subgroups. Finally, most new antiplatelet agents that are commercially available have not been studied in a PAD population. Given a general paucity of high-quality studies in patients with PAD, it is encouraging that recent, large RCTs have begun to focus enrollment on a pure PAD population, rather than on a mix of high-risk patients (CAD, cerebrovascular disease, and PAD).
Conclusions
Our findings favor clopidogrel as the monotherapy antiplatelet agent for patients with PAD, although this is based on a subgroup analysis of 1 large RCT and, with the introduction of the generic drug into clinical practice, may have important implications for health plans and medical systems. For studies aimed at improving the outcomes of patients with PAD, clopidogrel monotherapy seems justified as the current standard of care. More data are needed to understand standard of care for postrevascularization patients.
